• Loading stock data...
Est. 2004

Friday 02/22/2019

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More


  • 5:29 PM

    Aug 19, 2016 OTC Disclosure & News Service – Xenetic Biosciences, Inc. XBIO, (OTCQB: XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company developing next-generation biologic drugs and novel orphan oncology therapeutics, announced today that an Investigational New Drug (IND) application for the Company’s product candidate, Virexxa® (sodium cridanimod), has been allowed to proceed by the U.S. Food and Drug Administration (FDA). This enables Xenetic to initiate a Phase 2 clinical study of Virexxa in conjunction with progestin therapy for the

    Read more
  • 3:32 PM

    LEXINGTON, MA— XBIO, (Marketwired – February 12, 2016) – Xenetic Biosciences, Inc. (OTCQB: XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics (“Xenetic”) announced today that OPKO Health, Inc. (NYSE: OPK) has acquired an approximate 6.3% interest in Xenetic. Commenting on the investment in Xenetic, Dr. Phillip Frost, CEO and Chairman of OPKO Health, Inc., stated, “Xenetic has many novel technologies that address unmet needs in various orphan cancer indications, and we believe the science

    Read more
Public Wire Banner